Study Summary
This trial is testing a new drug, YY-15293, to see if it is safe and effective in treating patients with advanced solid tumors (cancer that has spread) with a KRAS G12C mutation.
- Advanced Solid Tumors
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Throughout the study for approximately 2 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
YL-15293
1 of 1
Experimental Treatment
55 Total Participants · 1 Treatment Group
Primary Treatment: YL-15293 · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there still openings for enrolment in this trial?
"Confirmed. Clinicaltrials.gov reports that this medical experiment was initially announced on November 9th 2021 and has been most recently updated on the 11th of the same month, indicating it is actively seeking participants." - Anonymous Online Contributor
What is the current intake quota for this clinical trial?
"The sponsor, Shanghai YingLi Pharmaceutical Co. Ltd., must enroll 55 qualified participants across multiple sites; including Oncology Consultants in Houston and Innovative Clinical Research Institute in Whittier." - Anonymous Online Contributor